BioCentury | Sep 16, 2020
Deals

Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology

...armored CAR T cell therapy to treat GPC3-expressing...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

...are exploring, HER2 is seeing the most activity, with 11 CAR T programs in development. GPC3...
...to treat unresectable metastatic colorectal cancer (see “Nov. 11 SITC Roundup” ). Targets GPC3 - Glypican 3...
...2 (EZH2) Fibroblast activation protein (FAP) Folate receptor 1 (FOLR1) (FR-alpha) (FOLR) Ganglioside GD2 (GD2) Glypican 2 (GPC2) GnRH/LHRH receptor Glypican 3 (GPC3) Epidermal...
BioCentury | Nov 8, 2019
Preclinical News

Nov. 7 Preclinical Quick Takes: NIH drafts policy requiring more data sharing; plus Unum, Mission-BioLegend, DCprime and more

...Society for Immunotherapy of Cancer (SITC) meeting in Fort Washington, Md. BOXR1030, which expresses a GPC3-targeting...
...complete response rates compared with anti-PD-1 monotherapy. Targets: GOT2 - Glutamic-oxaloacetic transminase 2; GPC3 - Glypican 3...
BioCentury | Oct 1, 2019
Company News

Oct. 1 Company Quick Takes: NVS, Microsoft to use AI for drug R&D; plus AstraZeneca, Tmunity-CHOP and AGTC-Otonomy deals

Novartis, Microsoft partner on AI for drug R&D Novartis AG (NYSE:NVS; SIX:NOVN) is partnering with Microsoft Corp. (NASDAQ:MSFT) to use artificial intelligence for drug development, with an initial focus on personalized macular degeneration therapies, cell...
BioCentury | Sep 4, 2019
Company News

Sept. 4 Company Quick Takes: Boehringer licenses Lupin MEK inhibitor; plus BMS-BioMotiv, KemPharm-GPC, Lilly, Nektar and Intellipharmaceutics

BI licenses Lupin's MEK inhibitor Boehringer Ingelheim (Ingelheim, Germany) licensed development and commercialization rights to MEK inhibitor LNP3794 from Lupin Ltd. (NSE:LUPIN; BSE:500257), which the pharma plans to test in combination with its KRAS inhibitors...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...group at Baylor College of Medicine describes the design of a Phase I trial for GPC3-targeted...
...Epidermal growth factor receptor EGFRvIII - Epidermal growth factor receptor variant III GPC3 - Glypican 3...
...ligand 3 (DLL3) Epidermal growth factor receptor (EGFR) (ErbB1) (HER1) Epidermal growth factor receptor variant III (EGFRvIII) Glypican 3 (GPC3) Lymphocyte-activation...
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

...Hospital EGFR806 CAR T cells Brain cancer Ph I Glypican 3 (GPC3) CARsgen Therapeutics Co. Ltd. CAR-GPC3...
BioCentury | Nov 2, 2018
Targets & Mechanisms

FDA’s pediatric target picks

FDA is looking ahead of industry in its guideline on targets for pediatric oncology, which includes more than 50 not yet in company pipelines in a list of over 220 the agency has its eye...
BioCentury | Sep 14, 2018
Clinical News

CARsgen solid tumor CAR T leads to complete response

...cell leukemia and lymphoma, EGFR/epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma, and glypican 3 (GPC3...
BioCentury | Sep 10, 2018
Clinical News

CARsgen solid tumor CAR T leads to complete response

...cell leukemia and lymphoma, EGFR/epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma, and glypican 3 (GPC3...
Items per page:
1 - 10 of 435